Chemistry:Amcenestrant
From HandWiki
Amcenestrant is a novel oral selective estrogen receptor degrader (SERD) that is being evaluated for the treatment of estrogen receptor-positive (ER+) breast cancer.[1]
Phase III trial for breast cancer in Japan had started, but this trial has been discontinued.[2]
References
- ↑ "GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer". Journal of Medicinal Chemistry 64 (16): 11841–11856. August 2021. doi:10.1021/acs.jmedchem.1c00847. PMID 34251202.
- ↑ "Amcenestrant - Sanofi". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800048980.
Further reading
- "Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review". Cancer Treatment Reviews 130: 102825. November 2024. doi:10.1016/j.ctrv.2024.102825. PMID 39293125.
- "Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer". European Journal of Pharmacology 969: 176424. April 2024. doi:10.1016/j.ejphar.2024.176424. PMID 38402929.
- "Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment". Current Opinion in Oncology 34 (6): 635–642. November 2022. doi:10.1097/CCO.0000000000000892. PMID 36000362.
- "Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer". Expert Opinion on Investigational Drugs 31 (6): 515–529. June 2022. doi:10.1080/13543784.2021.1983542. PMID 34694932.
 |  |
